Creutzfeldt Jakob Disease News and Research

RSS

Creutzfeldt–Jakob disease or CJD (sometimes incorrectly referred to as mad cow disease) is a degenerative neurological disorder (brain disease) that is incurable and invariably fatal. It is the most common among the types of transmissible spongiform encephalopathy found in humans.

Key to treating neurodegenerative prion diseases may lie in ribosome, shows research

New research results from Uppsala University, Sweden, show that the key to treating neurodegenerative prion diseases such as mad cow disease and Creutzfeldt-Jakob disease may lie in the ribosome, the protein synthesis machinery of the cell. The results were recently published in the Journal of Biological Chemistry.

2 Jul 2013

Research findings could provide a way to treat onset, progression of Parkinson's disease

The earliest signs of Parkinson's disease can be deceptively mild. The first thing that movie star Michael J. Fox noticed was twitching of the little finger of his left hand.

23 Apr 2013

TSRI scientists identify new drugs for human prion disease

Human diseases caused by misfolded proteins known as prions are some of most rare yet terrifying on the planet—incurable with disturbing symptoms that include dementia, personality shifts, hallucinations and coordination problems.

4 Apr 2013

Fast-progressing hearing impairment linked to fatal Creutzfeldt-Jakob Disease

Rapid hearing loss in both ears may be a symptom of the rare but always-fatal Creutzfeldt-Jakob Disease and should be considered a reason for clinicians to test for the disorder.

15 Mar 2013

Iron imbalance caused by prion proteins leads to cell death in CJD, researchers find

An iron imbalance caused by prion proteins collecting in the brain is a likely cause of cell death in Creutzfeldt-Jakob disease (CJD), researchers at Case Western Reserve University School of Medicine have found.

14 Mar 2013

Study identifies how new ALS gene mutations cause other diseases of the brain, muscle and bone

Researchers supported by The ALS Association have discovered how mutations in new amyotrophic lateral sclerosis (ALS) genes cause not only ALS but also other diseases of the brain, muscle and bone.

4 Mar 2013

Baxter files FEIBA NF BLA with FDA for prophylactic treatment of hemophilia A or B

Baxter International Inc. today announced that the company has submitted a biologics license application (BLA) supplement to the U.S. Food and Drug Administration (FDA) for the approval of prophylaxis treatment of FEIBA NF [Anti-Inhibitor Coagulant Complex], Nanofiltered and Vapor Heated, in patients with hemophilia A or B and inhibitors.

From Baxter International Inc. 26 Feb 2013

Targeting CSF1R with selective inhibitors could help Alzheimer's

Scientists from the University of Southampton have identified the molecular system that contributes to the harmful inflammatory reaction in the brain during neurodegenerative diseases.

22 Feb 2013

GE Healthcare submits Optison sNDA to aid in detection of cardiovascular diseases

GE Healthcare today announced that it has filed a supplemental new drug application (sNDA) that will allow the company to manufacture Optison (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), within its own facility.

16 Jan 2013

Prion protein helps the brain to absorb zinc

Scientists from the University of Leeds have found that the protein called prion helps our brains to absorb zinc, which is believed to be crucial to our ability to learn and the wellbeing of our memory.

17 Oct 2012

CJD presents major diagnostic problems

Most patients with sporadic Creutzfeldt-Jakob disease are initially misdiagnosed, with most not receiving a correct diagnosis until they are two-thirds of the way through their disease course, show findings in the Archives of Neurology.

27 Sep 2012

FDA approves Baxter's GAMMAGARD LIQUID for multifocal motor neuropathy

Baxter International Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] as a treatment for multifocal motor neuropathy (MMN). This is the first immunoglobulin treatment approved for MMN patients in the United States, and it was approved for use with MMN patients in Europe in 2011.

From Baxter International Inc. 25 Jun 2012

Soon a single therapy for range of brain diseases like Parkinson’s and Alzheimer’s

In a study, published in Nature, researchers prevented brain cells dying in mice with prion disease. It is hoped the same method for preventing brain cell death could apply in other diseases. The findings are at an early stage, but have been heralded as “fascinating”.

8 May 2012

Mad cow disease raises concern but safety nets are in place says USDA

Four sick cows ever discovered in the U.S., the one announced Tuesday being the first since 2006, and no human version of the illness linked to eating U.S. beef, is not enough to worry about. “From simply a public health issue, I put it very, very low,” Cornell University food safety expert Martin Wiedmann said of the level of concern about mad cow disease. Maintaining confidence in exports fuels the nation's monitoring of the beef supply as much as continuing safety concerns, he said.

26 Apr 2012

Mod5 yeast prion contributes to cell survival under environmental stress

One of the greatest mysterious in cellular biology has been given a new twist thanks to findings reported in Science. Researchers at the RIKEN Brain Science Institute show that prions, proteins that transmit heritable information without DNA or RNA, can contribute to drug resistance and cellular adaptation. Their discovery of a yeast prion with these properties demonstrates the active role of the prion conversion in cellular fitness adaptation, providing new insights into the potentially broader function of prions in living organisms.

23 Apr 2012

Computer modeling supports theory that many dementias spread like prion diseases

A new technique for analyzing brain images offers the possibility of using magnetic resonance imaging (MRI) to predict the rate of progression and physical path of many degenerative brain diseases, report scientists at the San Francisco VA Medical Center and the University of California, San Francisco.

11 Apr 2012

Positive results from Allergan's BOTOX Phase III trials on idiopathic overactive bladder

Allergan, Inc. today announced that two Phase III clinical trials of BOTOX (onabotulinumtoxinA) as a potential treatment option for patients with idiopathic overactive bladder met their pre-specified primary endpoints.

29 Mar 2012

CSL Behring commences enrollment in SCIg PATH trial for CIDP

CSL Behring has announced that the first patient has been enrolled in the PATH study, an international clinical trial designed to evaluate the efficacy, safety, and tolerability of two different doses of subcutaneous immunoglobulin (SCIg), compared with placebo, in maintenance treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).

26 Mar 2012

Alzheimer's may spread through connected neurons

Alzheimer's disease and other forms of dementia may spread within nerve networks in the brain by moving directly between connected neurons, instead of in other ways proposed by scientists, such as by propagating in all directions, according to researchers who report the finding in the March 22 edition of the journal Neuron.

22 Mar 2012

Timely treatment with Berinert provides faster symptom relief for HAE patients

CSL Behring announced today that treatment with Berinert, C1 Esterase Inhibitor (Human) within six hours of the onset of an acute hereditary angioedema (HAE) attack provides faster symptom relief than later treatment, according to data presented at the 2012 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.

7 Mar 2012